ArticleFrontiers in chemistry2026
Active targeting towards bone cancer and metastases by pamidronate-bridged dinuclear platinum(II) complexes.
Article in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates (BPs) are clinically established bone-seeking agents that strongly bind to hydroxyapatite and selectively accumulate at sites of active bone remodeling. Among nitrogen-containing BPs, pamidronate (PAM) is widely used for the management of cancer-related bone complications and has also been associated with antiproliferative and pro-apoptotic effects in several tumor models. These properties make PAM an attractive ligand for the development of potential bone-targeted anticancer agents, particularly in the context of primary bone tumors and bone metastases, which are difficult to treat and are frequently associated with severe pain and skeletal complications. Platinum-based chemotherapeutics are effective anticancer agents, but their clinical use is often limited by poor tissue selectivity, systemic toxicity, and drug resistance. In this work, we report the synthesis and full characterization of two novel dinuclear platinum(II)-PAM complexes in which PAM acts as a bridging ligand between two platinum centers containing either an oxaliplatin-derived [Pt(1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.